GE HealthCare Technologies (GEHC) investor relations material

Market performance and demand trends

• Orders grew 11% on a two-year basis, with a book-to-bill ratio of 1.07x and a record $21.8 billion backlog.

• Revenue increased 2.9%, in line with guidance, driven mainly by existing products and strong commercial execution.

• New product launches, such as Vivid Pioneer, contributed but most growth came from established offerings.

• Customer surveys indicate robust demand, especially in the U.S.

• New products are expected to drive future orders and accelerate sales growth beyond the current 3%-4% range.

Cost management and inflationary pressures

• Inflationary impacts, including logistics and rare earth elements, led to $150 million in gross inflation and a memory chip cost surge.

• $250 million in total inflation was partially offset by price increases and cost actions, but guidance was reduced by $0.15.

• Adequate buffer for cost increases has been built in, with contingency for commodity price volatility.

• Tariff assumptions remain conservative, with potential upside if tariffs expire or are replaced favorably.

• Mitigation strategies include price adjustments, supplier changes, and use of free trade zones.

Product innovation and pipeline outlook

• Photon counting CT and Total Body PET are major upcoming launches, opening new market segments.

• Pipeline includes next-gen SPECT, MR with Freelium, Allia Moveo, and Flyrcado, all expected to drive mid-single-digit growth.

• Flyrcado is progressing, with a $50 million annual run rate in Q2 and confidence in reaching $500 million+ by 2028.

• Barriers to adoption for Flyrcado are being addressed through workflow optimization and radiopharmacy support.

• Manganese-based MRI contrast agent is in development, targeting a large and growing market.